$IXHL News

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Incannex Healthcare Secures U.S. Patent For Compositions And Methods Of Treatment For Obstructive Sleep Apnea

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Healthcare Receives AU$6.039M Under Australian Government's Research And Development Tax Incentive Program. Anticipates Additional AU$5.1M In Future R&D Tax Incentives Proceeds This Year

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

Alliance Global Partners Initiates Coverage On Incannex Healthcare with Buy Rating, Announces Price Target of $18

Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) Estimate

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Healthcare Says It Believes PSX-001 Development Program Aligns With Goals Outlined In Executive Order, Accelerating Medical Treatments For Serious Mental Illness

Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position